Stock listing
NASDAQ:ENSC Ensysce Biosciences, Inc. Stock
Home listing (NASDAQ) of Ensysce Biosciences, Inc.
Follow Ensysce Biosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ENSC
$0.421 USD -0.017 (-3.9%)
Close on Oct 30, 2026
- Day range
- $0.420 – $0.440 USDOct 30, 2026
- Volume
- 105,957 sharesOct 30, 2026
- Market cap
- $8.19M USDAt the close on Oct 30, 2026 · price × 19.46M shares outstanding
- 52-week range
- $0.230 – $2.230 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $6.14M USDMedian day 511,600 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ENSC · Home | $0.421 USD | -0.017 (-3.9%) | 105,957 | $0.427 | $0.440 | $0.420 | $0.438 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · NASDAQ:ENSC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.421 | -0.017 | -3.9% | $0.427 | $0.440 | $0.420 | 105,957 | |
| $0.438 | -0.014 | -3.2% | $0.447 | $0.472 | $0.431 | 176,315 | |
| $0.452 | +0.002 | +0.5% | $0.457 | $0.470 | $0.440 | 59,446 | |
| $0.450 | 0.000 | 0.0% | $0.454 | $0.473 | $0.420 | 399,813 | |
| $0.450 | -0.020 | -4.4% | $0.456 | $0.489 | $0.430 | 293,048 | |
| $0.471 | -0.041 | -7.9% | $0.518 | $0.523 | $0.470 | 237,132 | |
| $0.511 | -0.009 | -1.7% | $0.520 | $0.550 | $0.510 | 353,400 | |
| $0.520 | +0.021 | +4.2% | $0.493 | $0.528 | $0.493 | 290,100 | |
| $0.499 | -0.004 | -0.8% | $0.547 | $0.547 | $0.499 | 302,500 | |
| $0.503 | -0.015 | -2.9% | $0.520 | $0.525 | $0.500 | 234,600 | |
| $0.518 | -0.080 | -13.4% | $0.587 | $0.587 | $0.503 | 490,700 | |
| $0.598 | +0.037 | +6.6% | $0.560 | $0.599 | $0.550 | 323,200 | |
| $0.561 | -0.012 | -2.1% | $0.561 | $0.574 | $0.527 | 415,000 | |
| $0.573 | +0.017 | +3.1% | $0.536 | $0.620 | $0.532 | 1,218,500 | |
| $0.556 | +0.029 | +5.5% | $0.510 | $0.565 | $0.485 | 1,316,200 | |
| $0.527 | +0.069 | +15.1% | $0.480 | $0.548 | $0.480 | 2,677,400 | |
| $0.458 | +0.029 | +6.8% | $0.439 | $0.474 | $0.401 | 1,256,000 | |
| $0.429 | -0.001 | -0.2% | $0.436 | $0.439 | $0.417 | 195,100 | |
| $0.430 | +0.011 | +2.6% | $0.417 | $0.440 | $0.412 | 540,300 | |
| $0.419 | +0.024 | +6.1% | $0.390 | $0.440 | $0.390 | 601,300 | |
| $0.395 | -0.005 | -1.3% | $0.410 | $0.427 | $0.393 | 173,200 | |
| $0.400 | -0.016 | -3.8% | $0.420 | $0.420 | $0.395 | 198,900 | |
| $0.416 | -0.001 | -0.2% | $0.411 | $0.426 | $0.410 | 349,200 | |
| $0.417 | +0.016 | +4.0% | $0.404 | $0.429 | $0.404 | 167,700 | |
| $0.401 | -0.011 | -2.7% | $0.411 | $0.423 | $0.399 | 210,300 | |
| $0.412 | +0.012 | +3.0% | $0.405 | $0.419 | $0.401 | 141,800 | |
| $0.400 | -0.015 | -3.6% | $0.426 | $0.426 | $0.397 | 319,600 | |
| $0.415 | -0.014 | -3.3% | $0.430 | $0.441 | $0.407 | 363,000 | |
| $0.429 | +0.008 | +1.9% | $0.425 | $0.443 | $0.418 | 200,900 | |
| $0.421 | -0.037 | -8.1% | $0.450 | $0.458 | $0.419 | 537,700 | |
| $0.458 | +0.005 | +1.1% | $0.452 | $0.464 | $0.444 | 494,700 | |
| $0.453 | +0.005 | +1.1% | $0.450 | $0.465 | $0.440 | 391,100 | |
| $0.448 | -0.004 | -0.9% | $0.455 | $0.457 | $0.435 | 382,000 | |
| $0.452 | -0.029 | -6.0% | $0.476 | $0.476 | $0.440 | 315,900 | |
| $0.481 | -0.006 | -1.2% | $0.490 | $0.505 | $0.473 | 418,900 | |
| $0.487 | -0.029 | -5.6% | $0.520 | $0.523 | $0.477 | 561,000 | |
| $0.516 | +0.042 | +8.9% | $0.477 | $0.526 | $0.440 | 940,400 | |
| $0.474 | +0.001 | +0.2% | $0.480 | $0.498 | $0.461 | 673,100 | |
| $0.473 | +0.017 | +3.7% | $0.470 | $0.499 | $0.401 | 1,448,700 | |
| $0.456 | +0.016 | +3.6% | $0.440 | $0.459 | $0.412 | 550,400 | |
| $0.440 | -0.003 | -0.7% | $0.436 | $0.452 | $0.428 | 436,700 | |
| $0.443 | +0.055 | +14.2% | $0.400 | $0.448 | $0.377 | 1,392,000 | |
| $0.388 | -0.005 | -1.3% | $0.385 | $0.395 | $0.377 | 207,700 | |
| $0.393 | -0.007 | -1.8% | $0.390 | $0.410 | $0.385 | 528,500 | |
| $0.400 | +0.001 | +0.3% | $0.405 | $0.412 | $0.385 | 486,600 | |
| $0.399 | -0.013 | -3.2% | $0.400 | $0.410 | $0.390 | 567,600 | |
| $0.412 | +0.009 | +2.2% | $0.410 | $0.417 | $0.391 | 747,400 | |
| $0.403 | +0.042 | +11.6% | $0.361 | $0.416 | $0.355 | 1,698,300 | |
| $0.361 | -0.012 | -3.2% | $0.373 | $0.373 | $0.354 | 966,700 | |
| $0.373 | -0.005 | -1.3% | $0.371 | $0.375 | $0.362 | 778,200 | |
| $0.378 | -0.010 | -2.6% | $0.380 | $0.387 | $0.360 | 911,100 | |
| $0.388 | +0.003 | +0.8% | $0.369 | $0.390 | $0.368 | 1,555,600 | |
| $0.385 | +0.008 | +2.1% | $0.396 | $0.406 | $0.362 | 2,924,400 | |
| $0.377 | -0.023 | -5.8% | $0.376 | $0.420 | $0.360 | 2,601,100 | |
| $0.400 | +0.051 | +14.6% | $0.339 | $0.475 | $0.331 | 18,710,000 | |
| $0.349 | -0.050 | -12.5% | $0.380 | $0.382 | $0.331 | 2,742,500 | |
| $0.399 | -0.022 | -5.2% | $0.430 | $0.430 | $0.370 | 1,824,400 | |
| $0.421 | -0.010 | -2.3% | $0.427 | $0.505 | $0.420 | 3,711,000 | |
| $0.431 | -0.089 | -17.1% | $0.459 | $0.471 | $0.378 | 5,198,000 | |
| $0.520 | -0.004 | -0.8% | $0.484 | $0.550 | $0.473 | 15,653,900 | |
| $0.524 | +0.162 | +44.8% | $0.631 | $0.979 | $0.460 | 498,051,900 | |
| $0.362 | -0.022 | -5.7% | $0.335 | $0.400 | $0.312 | 7,793,700 | |
| $0.384 | +0.104 | +37.1% | $0.434 | $0.483 | $0.357 | 182,036,200 | |
| $0.280 | +0.027 | +10.7% | $0.247 | $0.294 | $0.247 | 122,336,400 | |
| $0.253 | -0.004 | -1.6% | $0.251 | $0.260 | $0.247 | 278,900 | |
| $0.257 | +0.004 | +1.6% | $0.261 | $0.261 | $0.250 | 134,900 |
- Ticker
- NASDAQ:ENSC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 21, 2026
Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai
Latest earnings call · Aug 18, 2026
Ensysce Biosciences (NASDAQ:ENSC) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Aug 6, 2026
Investor Presentation (August 2026)
Investor deck · 26 slides
Calls
Replays
Ensysce Biosciences (NASDAQ:ENSC) Q2 2026 Earnings Call
Tue, Aug 18, 2026 · 11:00 AM ET
Watch TranscriptEnsysce Biosciences (NASDAQ:ENSC) Q4 2023 Earnings Call
Thu, Mar 21, 2024 · 11:00 AM ET
Watch TranscriptEnsysce Biosciences (NASDAQ:ENSC) Q4 2022 Earnings Call
Tue, Apr 11, 2023 · 11:00 AM ET
Watch Transcript
Latest news
Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai
Oct 21, 2026
Closed $0.52 (+4.2%) on Oct 21, 2026
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
Sep 15, 2026
Closed $0.452 (-6.0%) on Sep 15, 2026
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Sep 14, 2026
Closed $0.481 (-1.2%) on Sep 14, 2026
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
Sep 2, 2026
Closed $0.443 (+14.2%) on Sep 2, 2026
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
Aug 31, 2026
Closed $0.393 (-1.8%) on Aug 31, 2026
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 13, 2026
Closed $0.40 (+14.6%) on Aug 14, 2026
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
Aug 6, 2026
Closed $0.524 (+44.8%) on Aug 6, 2026
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
Jul 14, 2026
Closed $0.293 (+6.2%) on Jul 14, 2026
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
Jun 26, 2026
Closed $0.301 (+6.4%) on Jun 26, 2026
Ensysce Biosciences Reports First Quarter 2026 Financial Results
May 15, 2026
Closed $0.317 (+13.2%) on May 18, 2026
Financings
Private placement of series C non-voting convertible preferred stock
Aug 13, 2026
Tranche closed: US$21.5M raised · US$321.79 a share · Cantor +1
Dealers: Cantor, UBS Investment Bank
Buyers: Ally Bridge Group (led the private placement); Perceptive Advisors; Dellora Investments; Ikarian Capital; Adage Capital Partners, L.P.
Use of proceeds: Advance CY200 through a randomized Phase 2 trial in CRPS Type 1 and prepare for registrational development
Decks
Investor Presentation (August 2026)
Investor deck · 26 slides · Aug 6, 2026
Investor Presentation (August 2026)
Investor deck · 23 slides · August 2026
Investor Presentation (January 2023)
Investor deck · 38 slides · Jan 19, 2023
Investor Presentation (May 2022)
Investor deck · 36 slides · May 17, 2022
Ensysce Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 170 in all · newest Oct 21, 2026 · oldest 2021
- Calls
- 7 calls with a replay · 7 with a transcript · latest Aug 18, 2026
- Decks
- 8 decks · latest Aug 6, 2026
Where Ensysce Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ENSC · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ENSC | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Ensysce Biosciences, Inc.